Ruti Aga's Six-Year Ban: A Forged Prescription, a Misreported Drug Class, and the Medical Vacuum Beneath Ethiopian Marathon Running

That prescription was never written in a hospital. The clinic printed on it does not exist. The person who signed it was not a registered physician — it was a member of Ruti Aga's own family, who, when questioned, said he had used "an old prescription pad from a former workplace." That former workplace has since disowned the claim in plain words.

That single slip of paper is the centre of this case. Ruti Aga of Ethiopia — champion of the 2026 Tokyo Marathon, three-time World Marathon Majors runner-up, aged 32 — has been banned for six years. The Athletics Integrity Unit (AIU) announced it on Thursday. Two of those six years are for the presence of a prohibited substance; four are for fabricating the prescription.

The consequence is that an athlete who ran at 2:18 level will not return to a start line before she is 38. And the ban is not for the drug the newspapers called a "steroid." It is for the paper.

Aga's career belongs to the densest era of Ethiopian women's marathoning. Public records place her personal best in the 2:18 range — second at Berlin 2026, the Tokyo 2026 title, three World Marathon Majors podiums in all. That is the level at which an athlete reaches a Major start line, but it does not buy a national-team place; in Ethiopia a 2:18 runner can still be eliminated at a selection trial.

In March this year she won a half marathon in China. The name of the race, the time, the splits, the quality of the field — none of it appears in the AIU statement. What appears is this: a sample taken after the race returned methylprednisolone. She had been on provisional suspension since 10 September, and Thursday's decision set the six-year ban running from the same date.

The heaviest part of the statement is not the substance but the defence. Aga said she had a knee injury and took the drug as treatment. What the investigation found was that the clinic issuing the prescription did not exist, the signatory was not a registered medical practitioner, and the former employer of the man who claimed an "old pad" stated clearly that no such pad ever came from them. Three independent verification failures, on one document.

A technical correction is necessary here, because the whole case rests on it. Methylprednisolone is not a steroid — it is a glucocorticoid, class S9 on the WADA Prohibited List. Anabolic steroids sit in class S1. The difference is not semantic: S9 glucocorticoids are prohibited in-competition only, and only by injection, oral or rectal routes. A knee injection administered out-of-competition is entirely lawful.

Which means this was never a case about "taking steroids." It was a case about route and timing. In road racing the testing window opens at 23:59 the day before the race, so an injection given days earlier can still be caught if residue is present in-competition. A properly managed athlete has two paths: a Therapeutic Use Exemption, or observance of the prescribed washout period. Neither is visible in Aga's case — and that is the actual story.

The arithmetic of the sanction is simple: two years for presence, four for tampering. Six in total. That sum is itself a statement. Two years means the panel accepted presence as proven but did not treat intent as aggravated — in other words, the no-significant-fault mitigation was not granted. Four years is the Code's standard tampering sanction. The interesting paradox is that a forged prescription is itself circumstantial evidence of concealment intent, yet it did not escalate the presence sanction; it was carved out as a separate limb.

For me the most important part of this case is what the statement leaves out. A 2:18-level marathoner had no credentialed team physician. A knee injury was treated by a family member with no medical registration. This is not a filing error; it is a portrait of a system in which athletes depend on people they trust rather than on administrative support.

Bhubaneswar 2026, the evening I called the stadium's "first roar," was in truth a roar inside a half-empty stand — and what I saw that night was that a young athlete's entire support system rests on three or four people: a coach, a physio, and often a relative who becomes the "manager." Aga's case is the mature version of that structure, in which the relative also became the doctor.

China's label-race circuit is a distinct economic tier for East African marathoners: good appearance fees between Majors, low risk, few races. That same tier has now become the AIU's highest-yield testing ground. The appearance-fee economy and the testing economy are colliding inside the same races, and the athlete without formal medical support is the first to fall in that collision.

The career maths is brutal. Six years at 32 means a return at 38. Ethiopian women's marathon depth is such that a 38-year-old with a doping record is effectively unselectable. Technically it is a six-year ban; in practice it is the end of a career.

One thing survives: the 2026 Tokyo title. The violation is anchored to that March race, and absent a finding of earlier use, results before that date are not automatically annulled. The statement does not specify the scope of disqualification — information missing from the report that the AIU should have clarified. Standard practice says the result and prize money from the race where the sample was collected are voided; that is not stated here.

Which produces a counter-intuitive reading that questions athletics' whole sanctioning culture. This six-year ban will be cited worldwide as proof of AIU rigour. But the substance it rests on has no proven endurance benefit — a glucocorticoid reduces pain and swelling, it does not raise aerobic capacity. Several anabolic-steroid cases have drawn shorter bans.

The real asymmetry is not in the length of the sanction but in the direction of the investigation. This case did not begin with a drug; it began with a document. The AIU's enforcement frontier has shifted from detection to document verification. And when document verification concentrates on the same East African road-racing clusters where medical support is informal, the sanction records the gap rather than closing it.

The media played its part. Printing "steroid" was not merely a technical slip — it forced the case into a frame where no defence appears possible. Whereas a legitimate defence line did exist: route, timing, medical necessity. The forged prescription destroyed that line, but the public narrative never understood it in the first place. A competent defence, with genuine medical records and correct washout timing, might have avoided the tampering charge altogether — and closed the presence matter at a far lower sanction.

An appeal is open but weak. The CAS window is typically about 21 days from the reasoned decision, and a document-based tampering finding is hard to overturn. There is another layer entirely outside AIU jurisdiction: potential criminal exposure at national level for document forgery, unmentioned in this statement.

I learned to wait in Russia the way snow learns to fall — slowly, then all at once. This case requires no waiting; the arithmetic is clear. The question is when the next one arrives. In training clusters served by the same informal medical networks, there will be more of these prescriptions. Real reform will come when a federation's budget pays for a team doctor — not when another 32-year-old asks a relative to manufacture her treatment records.